CMPS Q1 beat accelerates FDA path — shorts caught offside

COMPASS Pathways reported Q1 earnings on May 13 that beat estimates and flagged an accelerated FDA review timeline, delivering a jolt to a stock that had already climbed 69% over the prior month — and leaving a still-elevated short base scrambling to adjust.

The earnings beat was clear. COMPASS posted Q1 EPS of -$0.30 against a -$0.34 consensus estimate, and shares surged on the headline. The company's FDA review is now described as accelerated, giving the psilocybin therapy programme for treatment-resistant depression a tighter path toward potential approval than the market had been pricing. With cash runway through 2028, management framed this as a period when operating discipline and launch readiness take precedence over any near-term revenue uncertainty. The stock gave back 2.9% on May 12 — the day before earnings — but the week as a whole finished up around half a percent heading into the catalyst.

Positioning, however, told a charged story going into today's print. Short interest was running at roughly 16.4% of the free float on May 12, down sharply from a recent peak near 18.9% in late April, as roughly 1.4 million shares of short interest unwound over the week. The retreat was notable: SI had built from around 11% in early April to that late-April high, a move that accumulated during a period of regulatory uncertainty — and it has been retreating ever since. Borrow availability remained loose at ~30% on the lending side, having eased considerably from a tighter 40–70% availability range seen across much of April, and the cost to borrow is negligible at 0.53%. The short score eased to 60.7 from 65 earlier in the week, consistent with covering activity rather than fresh positioning. Options, meanwhile, tilted toward calls: the put/call ratio dropped to 0.67, running roughly 1.4 standard deviations below its 20-day average of 0.74 — the market was leaning bullish into results.

The Street broadly agrees on direction, though targets vary widely. Multiple firms hold Buy ratings: BTIG reiterated today with a $14 target, Jefferies initiated last week at $18, and B. Riley Securities initiated at $17 in late April. Morgan Stanley (Overweight, $16) and Canaccord (Buy, $18) had trimmed targets in late March after a prior data release but maintained positive ratings. The mean price target of $21.57 implies more than 100% upside from Tuesday's $9.37 close — a gap that reflects genuine uncertainty about timing and commercial viability rather than straightforward conviction. One outlier target at $70 from HC Wainwright looks disconnected from the cluster and is best treated as a separate scenario. Analyst consensus ranks in the 99th percentile for return potential across the universe, a sign that the coverage base is heavily skewed toward buyers. The P/B multiple has expanded sharply — up roughly 38% over 30 days — mirroring the stock's re-rating through the rally.

ARK Investment Management added over 1.1 million shares through April 30, bringing its stake to 2.16 million shares (roughly 1.6% of outstanding), the most active institutional move in recent filings. Toronto-Dominion nearly doubled its position to 2.5 million shares in the same period. Against that, AtaiBeckley trimmed 1 million shares in January, and the stock's founding co-investors George Goldsmith and Ekaterina Malievskaia hold steady at roughly 1.5% apiece. Insider activity has been limited to small, routine sells by the CEO and CFO earlier in the year — all at prices well below current levels — and no insider has purchased shares in the visible history.

The next focal point is the FDA approval timeline itself, as the accelerated review designation transforms each regulatory update into a potential binary event. The 16% short interest still outstanding means any approval-adjacent headline will meet a crowded-against-the-grain positioning setup — not as stretched as the late-April peak, but far from neutral.